PURPOSE:TNFerade biologic is a novel means of delivering tumor necrosis factor alpha to tumor cells by gene transfer. We herein report final results of the largest randomized phase III trial performed to date among patients with locally advanced pancreatic cancer (LAPC) and the first to test gene transfer against this malignancy. PATIENTS AND METHODS: In all, 304 patients were randomly assigned 2:1 to standard of care plus TNFerade (SOC + TNFerade) versus standard of care alone (SOC). SOC consisted of 50.4 Gy in 28 fractions with concurrent fluorouracil (200 mg/m(2) per day continuous infusion). TNFerade was injected intratumorally before the first fraction of radiotherapy each week at a dose of 4 × 10(11) particle units by using either a percutaneous transabdominal or an endoscopic ultrasound approach. Four weeks after chemoradiotherapy, patients began gemcitabine (1,000 mg/m(2) intravenously) with or without erlotinib (100 to 150 mg per day orally) until progression or toxicity. RESULTS: The analysis included 187 patients randomly assigned toSOC + TNFerade and 90 to SOC by using a modified intention-to-treat approach. Median follow-up was 9.1 months (range, 0.1 to 50.5 months). Median survival was 10.0 months for patients in both the SOC + TNFerade and SOC arms (hazard ratio [HR], 0.90; 95% CI, 0.66 to 1.22; P = .26). Median progression-free survival (PFS) was 6.8 months for SOC + TNFerade versus 7.0 months for SOC (HR, 0.96; 95% CI, 0.69 to 1.32; P = .51). Among patients treated on the SOC + TNFerade arm, multivariate analysis showed that TNFerade injection by an endoscopic ultrasound-guided transgastric/transduodenal approach rather than a percutaneous transabdominal approach was a risk factor for inferior PFS (HR, 2.08; 95% CI, 1.06 to 4.06; P = .032). The patients in the SOC + TNFerade arm experienced more grade 1 to 2 fever and chills than those in the SOC arm (P < .001) but both arms had similar rates of grade 3 to 4 toxicities (all P > .05). CONCLUSION:SOC + TNFerade is safe but not effective for prolonging survival in patients with LAPC.
RCT Entities:
PURPOSE:TNFerade biologic is a novel means of delivering tumor necrosis factor alpha to tumor cells by gene transfer. We herein report final results of the largest randomized phase III trial performed to date among patients with locally advanced pancreatic cancer (LAPC) and the first to test gene transfer against this malignancy. PATIENTS AND METHODS: In all, 304 patients were randomly assigned 2:1 to standard of care plus TNFerade (SOC + TNFerade) versus standard of care alone (SOC). SOC consisted of 50.4 Gy in 28 fractions with concurrent fluorouracil (200 mg/m(2) per day continuous infusion). TNFerade was injected intratumorally before the first fraction of radiotherapy each week at a dose of 4 × 10(11) particle units by using either a percutaneous transabdominal or an endoscopic ultrasound approach. Four weeks after chemoradiotherapy, patients began gemcitabine (1,000 mg/m(2) intravenously) with or without erlotinib (100 to 150 mg per day orally) until progression or toxicity. RESULTS: The analysis included 187 patients randomly assigned to SOC + TNFerade and 90 to SOC by using a modified intention-to-treat approach. Median follow-up was 9.1 months (range, 0.1 to 50.5 months). Median survival was 10.0 months for patients in both the SOC + TNFerade and SOC arms (hazard ratio [HR], 0.90; 95% CI, 0.66 to 1.22; P = .26). Median progression-free survival (PFS) was 6.8 months for SOC + TNFerade versus 7.0 months for SOC (HR, 0.96; 95% CI, 0.69 to 1.32; P = .51). Among patients treated on the SOC + TNFerade arm, multivariate analysis showed that TNFerade injection by an endoscopic ultrasound-guided transgastric/transduodenal approach rather than a percutaneous transabdominal approach was a risk factor for inferior PFS (HR, 2.08; 95% CI, 1.06 to 4.06; P = .032). The patients in the SOC + TNFerade arm experienced more grade 1 to 2 fever and chills than those in the SOC arm (P < .001) but both arms had similar rates of grade 3 to 4 toxicities (all P > .05). CONCLUSION: SOC + TNFerade is safe but not effective for prolonging survival in patients with LAPC.
Authors: R Datta; E Rubin; V Sukhatme; S Qureshi; D Hallahan; R R Weichselbaum; D W Kufe Journal: Proc Natl Acad Sci U S A Date: 1992-11-01 Impact factor: 11.205
Authors: Sonja Gillen; Tibor Schuster; Christian Meyer Zum Büschenfelde; Helmut Friess; Jörg Kleeff Journal: PLoS Med Date: 2010-04-20 Impact factor: 11.069
Authors: D R Spriggs; M L Sherman; H Michie; K A Arthur; K Imamura; D Wilmore; E Frei; D W Kufe Journal: J Natl Cancer Inst Date: 1988-09-07 Impact factor: 13.506
Authors: Vinay K Gupta; James O Park; Nora T Jaskowiak; Helena J Mauceri; Saraswathy Seetharam; Ralph R Weichselbaum; Mitchell C Posner Journal: Ann Surg Oncol Date: 2002-06 Impact factor: 5.344
Authors: H J Mauceri; M A Beckett; H Liang; H G Sutton; S Pitroda; E Galka; E Efimova; T Darga; N N Khodarev; C R King; M C Posner; S Hellman; D W Kufe; R R Weichselbaum Journal: Cancer Gene Ther Date: 2008-10-31 Impact factor: 5.987
Authors: T D Chung; H J Mauceri; D E Hallahan; J J Yu; S Chung; W L Grdina; S Yajnik; D W Kufe; R R Weichselbaum Journal: Cancer Gene Ther Date: 1998 Nov-Dec Impact factor: 5.987
Authors: Monica Trevino; Susan Padalecki; Anand Karnad; Alberto Parra; Steve Weitman; Melissa Nashawati; Brad H Pollock; Amelie Ramirez; Ian M Thompson Journal: J Community Med Health Educ Date: 2013-09-01
Authors: Leticia Perondi Luz; Mohammad Ali Al-Haddad; Michael Sai Lai Sey; John M DeWitt Journal: World J Gastroenterol Date: 2014-06-28 Impact factor: 5.742
Authors: Margaret G Keane; Konstantinos Bramis; Stephen P Pereira; Giuseppe K Fusai Journal: World J Gastroenterol Date: 2014-03-07 Impact factor: 5.742
Authors: Maureen L Aliru; Jonathan E Schoenhals; Bhanu P Venkatesulu; Clark C Anderson; Hampartsoum B Barsoumian; Ahmed I Younes; Lakshmi S K Mahadevan; Melinda Soeung; Kathryn E Aziz; James W Welsh; Sunil Krishnan Journal: Immunotherapy Date: 2018-02-01 Impact factor: 4.196